Not all individuals with CLL need therapy. In spite of all current advances, the iwCLL continue to recommends watchful observation for sufferers with asymptomatic disease.86 This advice is based on no less than two randomized trials comparing observation to both chlorambucil monotherapy or fludarabine, cyclophosphamide and rituximab (FCR)."Berdasar